Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Cash & Current Investments (2016 - 2025)

AC Immune has reported Cash & Current Investments over the past 11 years, most recently at $114.3 million for Q4 2025.

  • Quarterly Cash & Current Investments rose 246.48% to $114.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $114.3 million through Dec 2025, up 246.48% year-over-year, with the annual reading at $114.3 million for FY2025, 246.48% up from the prior year.
  • Cash & Current Investments was $114.3 million for Q4 2025 at AC Immune, down from $135.6 million in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $125.9 billion in Q4 2021 and troughed at -$78.1 million in Q4 2024.
  • The 5-year median for Cash & Current Investments is $123.7 million (2024), against an average of $10.0 billion.
  • Year-over-year, Cash & Current Investments soared 59519.71% in 2021 and then tumbled 147.77% in 2024.
  • A 5-year view of Cash & Current Investments shows it stood at $125.9 billion in 2021, then plummeted by 99.9% to $127.2 million in 2022, then grew by 28.41% to $163.4 million in 2023, then tumbled by 147.77% to -$78.1 million in 2024, then soared by 246.48% to $114.3 million in 2025.
  • Per Business Quant, the three most recent readings for ACIU's Cash & Current Investments are $114.3 million (Q4 2025), $135.6 million (Q3 2025), and $166.3 million (Q2 2025).